TABLE 2.
Subject characteristics at baseline and at 6-wk follow-up1
| 6-wk Follow-up |
||||
| Baseline (total n = 272) | Reported change in supplement use (n = 45) | Did not report change in supplement use (n = 227) | P | |
| Age (y) | 58.1 ± 10.62 | 54.2 ± 8.9 | 58.9 ± 10.7 | 0.006 |
| Sex [n (%)] | 0.07 | |||
| Women | 193 (71.0) | 37 (80.4) | 156 (68.4) | |
| Men | 79 (29.0) | 8 (19.6) | 71 (31.6) | |
| Race [n (%)] | 0.85 | |||
| White | 221 (81.3) | 37 (82.2) | 184 (81.1) | |
| African American | 51 (18.8) | 8 (17.8) | 43 (18.9) | |
| Educational level [n (%)] | 0.53 | |||
| <4 y of college | 86 (31.6) | 16 (35.6) | 70 (30.7) | |
| ≥4 y of college | 186 (68.4) | 29 (64.4) | 157 (69.3) | |
| APOE status [n (%)] | <0.0001 | |||
| ϵ4− | 161 (59.2) | 13 (28.9) | 148 (65.1) | |
| ϵ4+ | 111 (40.8) | 32 (71.1) | 79 (34.8) | |
| Baseline supplement consumption [n (%)] | 0.02 | |||
| Yes | 138 (50.7) | 30 (66.7) | 108 (47.6) | |
| No | 134 (49.3) | 15 (33.3) | 119 (52.4) | |
| Randomization arm [n (%)] | 0.006 | |||
| Condensed | 182 (66.9) | 38 (84.4) | 144 (20.9) | |
| Extended | 90 (33.1) | 7 (15.5) | 83 (79.1) | |
| Number of affected relatives [n (%)] | 0.13 | |||
| 1 | 155 (57.0) | 21 (53.3) | 134 (59.0) | |
| >1 | 117 (43.0) | 24 (46.7) | 93 (41.0) | |
1
−, absence of the risk-increasing ϵ4 allele; ϵ4+, having at least one copy of the risk-increasing ϵ4 allele.
2
Mean ± SD (all such values).